Navigation Links
Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data

her vital organs that can ultimately lead to heart failure[6]. At present, high blood pressure is estimated to affect about one in four of all adults in the US, while approximately one billion people worldwide suffer from the condition. The number of people with high blood pressure is expected to reach nearly 1.6 billion by 2025[7].
Study details
This trial was a randomized, double-blind, multicenter study that compared the efficacy and safety of two doses of Exforge in patients with high blood pressure who had not reached goals with a single medicine. A total of 894 patients, of whom 145 (16%) had type 2 diabetes, were randomized to either Exforge (valsartan/amlodipine) 160/5 mg (n=443) or Exforge 160/10 mg (n=451). The majority of patients had previously taken either a calcium channel blocker (CCB), angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACE), beta blocker or diuretic. The primary endpoint measured the proportion of patients after eight and 16 weeks who reached the recommended treatment goals of blood pressure of <140/90 mmHg or a more aggressive goal of <130/80 mmHg.
Disclaimer
The foregoing release contains forward-looking statements which can be identified by the use of terminology such as, "can", "planned", "expected", or similar expressions, or by express or implied discussions regarding potential future revenue from Exforge. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Exforge will reach any particular sales levels. In particular, management's expectations regarding Exforge could be affected by, among other things, our ability
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
(Date:9/3/2015)... With a population of more than 1 ... also its single largest potential market for goods and ... all major world economies in the average rate of ... health expenditures. As an in vitro diagnostics (IVD) market, ... United States, western European countries, and Japan. China represents ...
(Date:9/3/2015)... , Sept. 3, 2015 This Defibrillators ... to save millions of lives across globe. This report ... Kingdom of Saudi Arabia . Stakeholders for ... suppliers, government agencies and regulatory bodies. The ... from two perspectives: by products and by end users. ...
(Date:9/3/2015)... ALISO VIEJO, Calif. , Sept. ... ), a leading global pharmaceutical company, and AqueSys, ... focused on developing ocular implants that reduce intraocular ... they have entered into an agreement under which ...  Under the terms of the agreement, Allergan will ...
Breaking Medicine Technology:IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
(Date:9/3/2015)... TX (PRWEB) , ... September 03, 2015 , ... ... pre-conference workshops included in Patient Experience Conference 2016, to be held April 13-15 ... non-provider or vendor hosted event bringing together the collective voices of healthcare leaders, ...
(Date:9/3/2015)... ... September 03, 2015 , ... DriButts, a ... partnered with Slingshot® Product Development Group to manufacture a long-lasting reusable diaper for ... with DriButts plans to bring 600 DriButts Diapers to rural areas of Haiti ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Real Time ... today announced that professional bull rider David Mason has signed an official endorsement deal ... at the age of six and his first bull at 15. He is an ...
(Date:9/3/2015)... FL (PRWEB) , ... September 03, 2015 , ... ... the Florida Companies to Watch for 2015 by economic development group ... of only 50 companies in the state selected for this prestigious award, which ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... investment landscape by connecting accredited and institutional investors to real estate investment opportunities ... designed to meet demand from both investors and sponsoring real estate companies. ...
Breaking Medicine News(10 mins):Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3
... Researchers at the University of Rochester when investigating for ... treated hot flashes as good as estrogen. ... the flow of calcium in and out of the ... ,flow risks like was researchers, who have been investigating ...
... making it mandatory for food manufacturers to add folate to ... organisation that monitors food standards in New Zealand is to ... ,Many live births and stillbirths each year ... as spina bifida, where one or more vertebrae fails to ...
... send to Australia for radiation therapy if the waiting ... oncology said, he has talked to Capital and Coast ... outside for treatment, either within New Zealand or to ... time for Wellington cancer patients, which has grown to ...
... a sigh of relief following the nod of approval ... the world’s first anti-AIDS cocktail drug for use as ... bulk drugs major Aurobindo Pharma, has made combined anti-retro ... (nevirapine) into a single three-in-one fixed dose drug. ...
... with greater determination from obscurity to a global emergency, the ... outpacing us, or are countries acting too slowly to address ... another 40 million worldwide? ,In early June, when ... meeting to the United Nations General Assembly's Special Session on ...
... India Institute of Medical Sciences has requested President A ... of reservation// and end to 'victimisation' of reserved category ... to the gherao of the sub-dean of the institute, ... President to exercise his moral authority and ask the ...
Cached Medicine News:Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2Health News:NZ To Opt For Folate Fortification Of Bread 2Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3
... typical patient, right for the not-so-typical patient., ... the ability to address the atypical situations ... themeven after implant. St. Jude Medical ICDs ... prepared in almost any situation, from high ...
... 105SL combines enhanced memory, processing ... and reliable all-metal construction. Proven ... and print speed make it ... who value reliability, productivity, consistent ...
... Built on the solid, tested ... six-inch labels --offers an unprecedented level ... placement as well as unique features ... into enterprise systems, automatic calibration, flexible ...
... The 220XiIII quickly prints labels ... at 10 ips. It is ... such as printing chemical drum ... automotive industry labels, banner-sized labels ...
Medicine Products: